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Abstract
Antimicrobial peptides play a pivotal role as key effectors of the innate immune system in plants and animals and
act as endogenous antibiotics. The molecules exhibit an antimicrobial activity against bacteria, viruses, and
eukaryotic pathogens with different specificities and potencies depending on the structure and amino-acid
composition of the peptides. Several antimicrobial peptides were comprehensively investigated in the last three
decades and some molecules with remarkable antimicrobial properties have reached the third phase of clinical
studies. Next to the peptides themselves, numerous organisms were examined and analyzed regarding their
repertoire of antimicrobial peptides revealing a huge number of candidates with potencies and properties for
future medical applications. One of these organisms is the horse, which possesses numerous peptides that are
interesting candidates for therapeutical applications in veterinary medicine. Here we summarize investigations and
knowledge on equine antimicrobial peptides, point to interesting candidates, and discuss prospects for
therapeutical applications.
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1. Introduction: Antimicrobial peptides - innate
antibiotics
Peptides with antimicrobial activities have been known
since 1922, when the first lysozyme was observed in
human tears by Alexander Fleming and Frederick Ridley
[1,2]. Currently over 1700 antimicrobial peptides are
known [3] and observed in all kingdoms of life [4-6].
Antimicrobial peptides are an essential part of the
innate immune system and act against bacteria, viruses,
fungi, parasites, and tumor cells [7,8].
1.1. Biological properties
The target specificity, killing efficacy, mode of action, and
biochemical properties vary between the peptides. In addi-
tion to their antimicrobial activity they can also act as
mediators of the adaptive immune system [9] and other
cellular processes like wound healing [10]. Most of the
peptides exhibit a cationic charge combined with an
amphipathic character. They act through an initial electro-
static interaction with the negatively charged compounds
of the bacterial cytoplasmic membrane followed by inser-
tion and permeabilization of the membrane. Mostly, mem-
brane integrity is dramatically disturbed resulting in lysis
of the targeted microbes [11,12]. However, antimicrobial
peptides can also influence intracellular processes through
interactions with receptors or signaling molecules and
mediate chemotactic or proinflammatory effects. Also by
receptor binding some antiviral peptides inhibit the inter-
action of the virus with the target cell [11,13,14].
1.2. Peptide characteristics
Antimicrobial peptides are defined as peptide molecules
with an antimicrobial activity, composed of less than
100 amino acids encoded by individual genes. In general
they consist of 12 to 50 amino acids including a large
proportion of cationic and hydrophobic residues [15].
They can be classified by structural or sequential simila-
rities or by conserved regions on both the amino acid
and nucleotide level [11,16,17]. Table 1 exemplifies a
classification scheme based on the tertiary structure.
Nevertheless, other classification criteria must be used
for peptides, whose mature forms possess structural
motifs of different classes. In such cases, an amino-acid
alignment of precursor peptides is more useful as shown
in section 3.5 (cathelicidins).
Antimicrobial peptides are synthesized constitutively or
after stimulation by proinflammatory or pathogen asso-
ciated molecules in circulating phagocytic cells, granulo-
cytes, epithelial cells of mucosal tissues, and glandular
cells [8,18]. In many cases they possess an N-terminal
signal peptide mediating correct subcellular sorting and
trafficking and an anionic propeptide which is thought to
be the major contributing factor inhibiting the antimicro-
bial activity by neutralizing the net positive charge of the
mature peptide [19,20]. The propeptides are cleaved by
endopeptidases after secretion into the extracellular
space (extracellular activation) or before they are incor-
porated into storage vesicles (intracellular activation)
[21,22].
1.3. Antimicrobial peptide genes
The anatomy of antimicrobial peptide genes differs
widely between peptide families. Most of them consist of
2-5 exons. Genes of structurally related antimicrobial
peptides are often arranged in clusters, indicating a com-
mon evolutionary ancestor [23-25]. The induction of the
antimicrobial peptide gene expression is mostly initiated
by binding of transcription factors like NF- B, AP-1,
and STAT3 [26] due to activation of Toll-like receptors
by microbial antigens or initiated by cytokines [27].
Mammals are equipped with various antimicrobial
peptides. The two major antimicrobial peptide families
in mammals are defensins and cathelicidins.
2. Antimicrobial peptides of the horse: history
and overview
Equine antimicrobial peptides analyzed so far are lyso-
zymes, cathelicidins, defensins, NK-lysin, psoriasin, hepci-
din, neutrophilic antimicrobial peptides with homologies
to granulins, and equinins. This chapter gives a historical
overview of the scientific highlights of the last decades and
a basic orientation about the magnitude of the peptides
discovered and analyzed.
O n eo ft h ef i r s te q u i n ea n t i m i c r o b i a lp r o t e i n so ft h e
horse, phagocytin, was already described in 1956 by Hirsch
[28]. The protein is rich in arginine and therefore pos-
sesses a net positive charge. Its antimicrobial activity is
pH-dependent and completely inhibited in the presence of
albumin. To date we know that these characteristics are
typical for antimicrobial peptides, but it remains unclear
to which family phagocytin belongs and whether it was
rediscovered later and denoted otherwise.
In 1972 Jáuregui-Adell et al. isolated the first equine
lysozyme with antimicrobial activity against streptococci
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further equine antimicrobial peptides were discovered
and only a few investigations with the known milk-
lysozyme were performed. But in the 1990s, studies
increased substantially starting with the discovery of a
second equine lysozyme that was isolated from neutro-
phil granulocytes and showed a potent antimicrobial
activity against Gram-negative and Gram-positive bac-
teria [31]. In 1992, two additional neutrophil-derived
antimicrobial peptides were found, equine neutrophil
antimicrobial peptide 1 (eNAP-1) and eNAP-2 [32,33].
Both peptides possess antimicrobial activities against
Gram-negative and Gram-positive bacteria, eNAP-2 acts
additionally as an inhibitor of microbial proteases [34].
In 1999, Scocchi et al. found three equine cathelicidins
in myeloid cells from bone marrow, termed eCATH-1
(equine cathelicidin-1), eCATH-2, and eCATH-3 [35].
Whereas all of these transcripts were found in myeloid
cells, only eCATH-2 and eCATH-3 were detected at the
peptide level. The synthetic variants were found to be
active against various bacteria and fungi.
The first defensin of the horse was identified by Davis et
al. in 2004 and named equine b-defensin-1 (eBD-1) [36].
Its transcript is expressed in various tissues. One year
later, Davis et al. also identified an equine NK(natural
killer cell)-lysin which is specifically expressed in lympho-
cytes [37]. The biological activities of eBD-1 and NK-lysin
are unknown. Also in 2005, the mRNA-sequence of the
equine psoriasin (a calcium-binding protein of the S100-
protein family with antimicrobial activities [38]) was
described and the gene was mapped to equine chromo-
some 5 [39].
A putative a-defensin and additional b-defensins in the
genome of the horse were detected in 2006 by analyzing
the sequence of an equine BAC-clone [40]. A compre-
hensive analysis of the defensins was performed in the
following years [41,42]. The antimicrobial activities and
the mode of action of the first equine a-defensin DEFA1
were investigated. In 2009, Bruhn et al. analyzed the full
repertoire of equine a-defensin transcripts in the intes-
tine and found 38 different equine a-defensin transcripts
[41]. The high number of potentially active a-defensins is
remarkable in mammalia, and within the subgroup of
Laurasiatheria the Equidae are the only known family
expressing a-defensin genes.
In 2010, two cathelicidin-derived antimicrobial pep-
t i d e sw e r ef o u n di nt h ed o n k e y( Equus asinus) denoted
as EA-CATH1 and EA-CATH2 [43]. The chemically
synthesized peptide variants exhibit antimicrobial activ-
ities against bacteria and fungi. Finally, equine hepcidin,
an antimicrobial peptide also involved in iron homeosta-
sis, was discovered and analyzed concerning its tissue
distribution.
3. The equine peptides in detail
Equine antimicrobial peptides have been detected on
mRNA or protein level, respectively, in numerous tis-
sues of the horse (Figure 1). Characteristics of the
Table 1 Typical structure motifs of mature antimicrobial peptides
Structure motif a-Helix b-Sheet Linear Loop structure Cyclic
Peptide example Magainin 2
[188]
PDB: 2MAG
Defensin
RK-1 [189]
PDB: 1EWS
Indolicidin [190]
PDB: 1G89
Thanatin [191]
PDB: 8TVF
Defensin RTD-1 [192]
PDB: 1HVZ
Ribbon model
Origin Frog
Xenopus laevis
Rabbit
Oryctolagus cuniculus
Cattle
Bos taurus
Bug
Podisus maculiventris
Monkey
Rhesus macaques
Disulfide bonds -3 - 1 3
Peptide structures obtained from the Protein Data Bank (PDB).
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ters are introduced by a description of the correspond-
ing peptide family in general.
3.1. Lysozymes
Lysozymes are glycoside hydrolases that cleave b-(1,4)-gly-
cosidic bonds of bacterial cell walls [44]. Three types of
lysozymes can be distinguished: c-type (chicken or con-
ventional type), g-type (goose-type) and i-type (inverte-
brate type) lysozyme. These types differ in their primary
structure and in their biochemical properties but their ter-
tiary structures own the same topology. The first lysozyme
tertiary structure was determined from hen egg white by
X-ray crystallography [45]. It shows two domains of a-
helical or b-strand character, respectively, that harbor the
active site between them. The in vivo antibacterial activity
of the lysozymes is limited by numerous general cell-wall
modifications hindering the enzyme to reach its substrate
[44]. This is compensated in vivo by a simultaneous attack
of a cocktail of components (defensins, cathelicidins) that
disrupt the membrane integrity. The more specialized
lysozyme inhibitors seem to be restricted to c-type lyso-
zymes. Nevertheless, by cleaving the major bacterial cell
wall component peptidoglycan lysozymes contribute to
the antibacterial defense, considerably.
3.1.1. Molecular properties of equine lysozyme (EL) and its
localization in the horse
The equine lysozyme consists of 129 amino acids and
possesses essential features of chicken-type lysozymes
[46]. It shows 50-51% sequence identity with human milk
lysozyme and with domestic hen egg white lysozyme.
Interestingly, it was found that EL binds calcium ions in
an equimolar ratio, whereas human and hen egg white
lysozyme do not [47,48]. As lysozymes are homologous
proteins of a-lactalbumins which can bind calcium, EL is
seen as an evolutionary link between lysozymes and
a-lactalbumins [49,50]. The binding of calcium by EL
influences its molecular structure and participates in EL
oligomer formation [51-53]. Structural studies of EL, its
calcium binding property and the EL oligomer formation
are reviewed in [50]. Two things have to be mentioned:
first, the tertiary structure of EL was never determined de
Figure 1 Expression of equine antimicrobial peptides in different tissues of the horse. Expression was detected on the mRNA-level or the
protein level, respectively, as indicated by superscript characters m and p. The picture “Internal organs of the horse” was provided with kind
permission by Virbac (
© Virbac).
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ment, respectively [48,54,55]. Second, very recently an
analysis of its calcium/magnesium selectivity revealed a
distinct additional magnesium-specific site in EL [56].
Many of the EL data summarized in this review origi-
nated from mare-milk lysozyme. However, there are sev-
eral other loci where lysozyme can be detected in the
horse, e. g. serum and plasma [57-60], synovial and uterine
fluids [59,61], intestinal Paneth cells [62,63] and granulo-
cytes [31] (Figure 1). Besides the secretory granules of
Paneth cells, EL was localized on the subcellular level in
the secretory granules, Golgi apparatus, and elements of
the rough endoplasmic reticulum of apocrine glands of
the equine scrotal skin [64].
3.1.2. Antimicrobial and cytotoxic activity of equine
lysozyme and its association with horse disease patterns
The antimicrobial activity spectrum of EL includes Gram-
positive bacteria as Streptococcus (Strep.) equines [30],
Micrococcus luteus, Bacillus subtilis,a n dStaphylococcus
(Staph.) lentus [31]. Staph. aureus and Staph. epidermidis
Table 2 Antimicrobial activities and characteristics of equine antimicrobial peptides
Peptide family
Peptide
Mass [kDa] Charge
(at pH 7.5)
Specificity Salt
dependency
Citation
Cathelicidins
eCATH-1
[GenBank: CAA12226]
3.1 8.8 Gram-positive/negative bacteria
Fungi
no
no
[35,111]
eCATH-2
[GenBank: CAA12227]
3.6 2.8 Gram-positive/negative bacteria
Fungi
no
yes
[35,111]
eCATH-3
[GenBank: CAA12228]
4.7 7.0 Gram-positive/negative bacteria
Fungi
yes
yes
[35,111]
eCATH-4
[GenBank: XP_001495199.2]
n. d. n. d. n. d. this review
EA-CATH-1
[GenBank: ACN93988.1]
3.1 6.8 Gram-positive/negative bacteria
Fungi
no
no
[43]
Defensins
DEFB1
[GenBank: AAO32801]
4.0 5.2 n. d. [36]
DEFL2
[GenBank: CAJ01792]
4.5 6.5 n. d. [40,145]
DEFL3
[GenBank: CAJ01793]
4.2 5.6 n. d. [40,145]
DEFB103
[GenBank: CAJ01801]
4.7 9.2 n.d. [40,145]
DEFA1
[GenBank: ABP96800]
4.1 6.3 Gram-positive/negative bacteria
Yeast
yes
yes
[40-42,131]
DEFA2 to 29
[GenBank: ACV49728-ACV49755]
3.6 - 5.5 2.3 - 9.2 n. d. [41]
Neutrophil antimicrobial peptides
eNAP-1
[GenBank: AAB22706]
7.2 n. d. Gram-positive/negative bacteria n. d. [33]
eNAP-2
[GenBank: AAB24353]
6.5 n. d. Gram-positive/negative bacteria n. d. [32,34]
Lysozymes
Equine lysozyme
[Swiss-Prot: P11376]
14.7 2.2 Gram-positive/negative bacteria n. d. [46-48,50]
NK-lysins
Equine NK-lysin
[GenBank: AAN10122]
9.2 7.2 n. d. [37,82]
Psoriasin (S100A7)
Psoriasin 1
[GenBank: CAH03717]
11.3 -6.2 Escherichia coli n.d. [39,100]
Hepcidin
Equine hepcidin
[GenBank: XM_001491610.2]
2.8 1.1 n. d. [158]
Peptide masses and charges that have not been determined experimentally were complemented using the ProteinCalculator v3.3 software [193].
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against the Gram-negative bacteria Escherichia (E.) coli,
Klebsiella (Kl.) pneumoniae, Bordetella bronchiseptica,a n d
Serratia (Ser.) marcescens.
The enzymatic activity of EL is dependent on several
factors. Whereas EL is still working after heating to 100°C
at acidic and neutral pH, its activity is markedly affected
by alkaline pH [65]. Interestingly, in female Arabian
horses, the activity of the enzyme was shown to follow a
seasonal periodicity [66]. Lysozyme activity in milk during
lactation revealed highest activities in the first three days
post partum [67]. This activity rapidly decreased until the
9
th day. In this regard, race and time of conception
revealed to be significantly important.
EL is able to form oligomers that can assemble to linear
or annular protofilaments [68]. Whereas the monomers
and the protofilaments are harmless, the oligomers are
cytotoxic and induce cell death in primary neuronal cells,
fibroblasts, and neuroblastoma cells [69]. Recently, EL
was found to assemble into multimeric complexes with
oleic acid (ELOA) which are also cytotoxic [70].
The association of equine lysozyme with several disease
patterns in the horse is proven by different studies mainly
by descriptive investigation of its expression level. In surgi-
cally induced cartilaginous defects in the radiocarpal joints
of horses, the synovial fluid lysozyme concentration was
found to be significantly increased and of lysosomal origin
[59]. Furthermore, the increased lysozyme concentration
was correlated positively with increased numbers of leuko-
cytes in the synovial fluid. Whereas the joint defects did
not influence the plasma lysozyme, in myelomonocytic
myeloproliferative disease the concentration of EL was
almost three times increased [57]. The plasma lysozyme
activity was also investigated in experimental fever induced
by administration of E. coli lipopolysaccharide (LPS) to
tarpan-like horses. Three hours after injection of LPS, the
plasma lysozyme level was significantly increased [60]. The
association of lysozyme with inflammation was also
observed with experimentally induced bacterial endome-
tritis. Lysozyme levels progressively increased in uterine
flushings with time after infection [61]. During acute
equine alimentary laminitis EL was secreted by degranula-
tion of Paneth cells in response to the deregulation of the
microbial balance in the gut. This finding suggests the
contribution of this enzyme to the mucosal defense system
of the equine intestinal tract [62]. The serum EL-concen-
tration in older horses (average age: 19 yr) after vaccina-
tion with virus was significantly changed depending on
vitamin-E supplementation. Supplemented animals did
not show an increase in contrast to placebo-treated horses
exhibiting a continuous increase of serum EL [71]. Finally,
EL is proposed to support the function of the cerumen as
a non-specific antimicrobial agent in the external auditory
canal [72].
3.2. NK-lysin
NK-lysin was first isolated from porcine small intestine
showing high antibacterial activity against E. coli and
Bac. megaterium [73]. It is a primary effector molecule of
cytotoxic T- and NK-cells [73,74]. NK-lysins are induci-
ble by cytokines, have a lytic activity against eukaryotic
cells except red blood cells, and additionally possess a
tumorolytic activity [73,75]. They were identified in cattle
[76], chicken [77], flounder [78], channel catfish [25],
horses [37], and Fasciola hepatica [79]. A related protein
family in humans is denoted as granulysins [80]. Interest-
ingly, NK-lysins show a homology to the amoebapores
derived from Amoeba indicating an evolutionary connec-
tion between the leukocytes of higher animals and their
unicellular protozoan ancestors [81].
3.2.1. Equine NK-lysin
The equine NK-lysin was described by Davis et al. in 2005
[37]. Its amino-acid sequence showed a similarity of 80%
compared with the porcine homolog and 69% with the
bovine homolog (Figure 2). The equine mature peptide
consists of 83 amino acids. Six cysteine residues that are in
general associated with the antimicrobial activity of the
peptide are conserved between the equine, porcine and
bovine primary structure. An additional seventh cysteine
residue can be found only in the equine amino-acid
sequence.
The transcription profile of the equine NK-lysin mRNA
was analyzed in more detail by separating the peripheral
blood mononuclear cell population. A transcript of the
equine NK-lysin was identified in lymphoid cells but not
in granulocytes. The authors concluded that equine NK-
lysin is ubiquitously expressed in equine lymphocytes as
for NK-lysins of other species [37].
To determine whether equine NK-lysin gene expression
is inducible, mononuclear cells were examined after stimu-
lation with concanavalin A (a lectin that stimulates lym-
phocytes). Treatment of lymphocytes with 1 μgo ft h e
mitogen leads to an increase in gene expression of
approximately 50% [37]. The antimicrobial activities of the
equine NK-lysin have not been determined up to now.
3.2.2. Inducibility of NK-lysin by stimulants
Davis et al. could show that treatment of horses with Pro-
pionibacterium (Pb.) acnes leads to an enhanced gene
expression of IFN-g and NK-lysin in peripheral blood
mononuclear cells [82]. Commercially available non-viable
Pb. acnes c e l l sc a nb eu s e da si m m u n es t i m u l a n t st h a t
activate macrophages and mononuclear cells, contributing
to an enhanced elimination of pathogens [83]. Immunosti-
mulation in horses with Pb. acnes led to an increased
number of CD4
+ lymphocytes and an enhanced phagocy-
tosing activity and lymphokine-activated killing [84].
These studies underline the beneficial responses of Pb.
acnes immunostimulation in horses and show that antimi-
crobial peptides are not only interesting as drugs, but also
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modulatory substances to promote the immune system.
3.3. Equine neutrophil antimicrobial peptides (eNAPs) and
equinins
Equine neutrophil derived antimicrobial peptides include
cathelicidins, lysozymes, eNAP-1, and eNAP-2. Interest-
ingly, neutrophils of the horse lack defensins that depict
mostly the main peptide type of these cells in other spe-
cies. The equine neutrophil peptides eNAP-1 and eNAP-2
do not share sequential similarities and are included in dif-
ferent peptide families [33]. Interestingly, both of these
families are not known as typical antimicrobials. Equine
NAP-1 shows a similarity to the peptide-group of granu-
lins, mainly known as cytokines of different species [33].
In contrast, eNAP-2 shows a homology to a peptide group
of equine microbial protease inhibitors denoted equinins.
In the original publication of Couto et al. eNAP-2 was
related to the rat WDNM1 protein which is included in a
four-disulfide core family of proteins with diverse func-
tions and a homology to human antileukoproteases [32].
3.3.1. eNAP-1
Approximately 0.5 μgo fe N A P - 1a n du pt o5μgo f
eNAP-2 were isolated from 10
9 polymorphonuclear leu-
kocytes (PMN), which represents comparatively only 1%
of the amount of stored defensins in human neutrophils
[33]. Defensins were absent in equine PMN.
Equine NAP-1 contains 10 cysteine residues that are
completely conserved compared to the peptide family of
granulins isolated from human neutrophils [85]. Whereas
granulins are known as growth factors and cell communi-
cation molecules with diverse biological functions but
without antimicrobial activities, eNAP-1 showed an anti-
microbial activity against three of four tested clinical iso-
lates of common equine uterine pathogens: Strep. equi
subsp. zooepidemicus, E. coli,a n dPs. aeruginosa. A bacter-
iostatic activity was observed against Kl. pneumoniae [33].
However, compared with the antimicrobial activities of,
e.g., defensins, eNAP1 possesses a rather weak antimicro-
bial activity.
3.3.2. eNAP-2
As in the case of eNAP-1, the amino-acid analysis of
eNAP-2 also revealed high cysteine content [32]. Its anti-
bacterial activity was assessed with the same equine patho-
gens that were already used for eNAP-1. The reduction of
the input CFU/mL was 94% for Strep. equi subsp. zooepi-
demicus at a peptide concentration of 100 μg/mL, 90.2%
in the case of E. coli, and 77.6% for Ps. aeruginosa. Kl.
pneumoniae was unaffected. These antimicrobial activities
were comparable to eNAP-1, but to some extent lower
against the tested Gram-positive strain Strep. equi subsp.
zooepidemicus [32]. However, whereas eNAP-1 is present
only in very low quantities in equine neutrophils, eNAP-2
seems to be one of the major gene products [32].
Equine NAP-2 was shown to be related to a peptide
called WDNM1 [86]. Five cysteine residues were highly
conserved between these peptides. WDNM1 is present in
rats, mice (also known as Expi, Kal1), and cattle. It acts as
an extracellular proteinase inhibitor and is associated with
cell differentiation processes, apoptosis and cancer [87,88].
Couto et al. showed the relationships between eNAP-2
and several four-disulfide core antiproteases and also the
relationships between eNAP-2 and equine cationic pep-
tides exhibiting selective inhibitory activity against subtili-
sin and proteinase K (later denoted equinins), reported by
Pellegrini et al. in 1988 [89]. In a follow-up study, Couto
et al. demonstrated the selective inhibition of microbial
serine proteases by eNAP-2 [34]. Equine NAP-2 inhibited
the microbial proteinases subtilisin A and proteinase K
and did not affect the enzymatic activity of human neutro-
phil elastase, human cathepsin G, or bovine pancreatic
trypsin. Additionally, it was demonstrated that eNAP-2
formed an enzyme-inhibitor complex with subtilisin A
and proteinase K but not with other tested proteinases.
The authors concluded that the dual antimicrobial and
antiproteinase activities of eNAP-2 might attribute the
Figure 2 Comparison of mature NK-lysins and granulysin from farm animals. Primary structure alignment of mature NK-lysins from the
horse and pig and granulysin from cattle. Conserved and semi-conserved amino-acid residues with similar properties are highlighted in light
grey, cysteine residues in dark grey. Similar amino acids were defined as follows: (A, G); (S, T); (E, D); (R, K, H); (Q, N); (V, I, L, M); (Y, F); (W); (P); (C)
[81]. The arrow indicates an additional cysteine residue only present in the equine sequence. Gaps introduced to maximize amino-acid
alignments are indicated by hyphens. The percent similarity to equine NK-lysin is given at the end of the pig/cattle sequence.
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infections [34].
3.3.3. Equinins
The antimicrobial activity of equinins (with the excep-
tion of eNAP-2) has not yet been proven, but they are
able to selectively inhibit the microbial proteinases sub-
tilisin and proteinase K. Equinins were discovered by
Pellegrini et al. in 1988 [89,90] and denoted as low-
molecular weight proteinase inhibitors/isoinhibitors
from the granular fraction of equine neutrophilic
granulocytes.
Five potential proteinase inhibitors isolated from the
granule-rich sediment of disrupted neutrophils were puri-
fied using chromatography techniques. The molecules
separated with molecular weights of 6.3 to 11.3 kDa were
tested for their inhibitory activities against 13 different
proteinases, but all five equine neutrophilic proteinase
inhibitors inhibited exclusively proteinase K and subtilisin.
Thus, the inhibitory activities are only directed against
microbial proteases and not against granule proteinases,
suggesting that they may act as endogenous antibiotics
[90]. In fact, the direct antimicrobial activities of the pro-
teinase inhibitors were not determined to date, but it is
possible that the inhibitors could interfere with acyl-serine
proteases involved in bacterial cell wall synthesis.
The equine neutrophilic proteinase inhibitors share their
target specificity with eNAP-2, but in contrast they were
stable at temperatures up to 100°C and the inhibitory
activity remained constant at a broad pH-range. The
membership of eNAP-2 to the proteinase inhibitors,
reported by Couto et al. [34], was confirmed by Pellegrini
et al. some years later [91]. They combined eNAP-2 and
the equine neutrophilic proteinase inhibitors to one group
denoted equinins.
3.4. Psoriasin (S100A7)
Psoriasin (S100A7) is a member of the S100-gene family
that represents the largest subgroup of the calcium-bind-
ing protein super-family [92]. The characteristic structural
motifs of the S100-gene family are two EF-hands, com-
prised of a helix-loop-helix unit, that are able to bind biva-
lent ions like calcium and zinc. Psoriasin was first
identified as a secreted protein in extracts of human skin
from psoriasis patients [93]. It is synthesized in keratino-
cytes and is highly upregulated in psoriatic skin [94] and
epithelial skin tumors [95]. It was shown that psoriasin is
a potent and selective chemotactic inflammatory protein
for CD4
+ T-cells and neutrophils [96]. The protein was
identified as the major E. coli killing factor in both healthy
and psoriatic skin, the human tongue, and the female geni-
tal tract [38,97,98]. Psoriasin acts by membrane permeabi-
lization, depending on the pH-value [99]. Members of
the S100 family have been identified in all vertebrates
observed to date and are clustered in the genome.
3.4.1. The equine psoriasin 1
The equine S100A7 gene, called psoriasin 1, was con-
firmed and assigned to chromosome 5p12-p13 in 2005
[39]. Its genomic sequence indicates that one intron of
approximately 1.1 kbp separates two exons. Comparative
studies with sequences from different species showed the
highest identities with human S100A7 (85%) and S100A7
of Bos taurus (80%). A transcriptional analysis showed the
existence of equine psoriasin 1 transcripts in skin, trachea,
esophagus, intestine, and vulva [100].
The equine psoriasin was synthesized recombinantly and
different oligomers were isolated and analyzed regarding
their antimicrobial activities and mode of action. A weak
antimicrobial activity against E. coli was observed for the
dimer as well as a weak pore-forming activity [100].
3.5. Cathelicidins
The first member of the cathelicidin family was isolated
from cattle in 1993 [101]. The term cathelicidins indicates
the evolutionary relationship of this protein family to the
cathelins. Cathelicidins consist of an N-terminal cathelin-
like sequence (~ 120-150 amino acids) and a C-terminal
cationic antimicrobial domain (~10-95 AA) [102,103]. The
antimicrobial domain, which is the mature cathelicidin pep-
tide, becomes active after cleavage from the N-terminus.
Cathelicidins are stored as holoproteins, precursors that
lack antimicrobial activity. They are synthesized predomi-
nately in myeloid cells and are stored in secretory granules
of neutrophils. They were also found in different epithelia,
organs, and secretions of glands (reviewed by [103] and
[104]).
In contrast to most of the other families of antimicro-
bial peptides, mature cathelicidins are highly heteroge-
neous. The reason for combining these diverse molecules
to one family is the highly conserved N-terminal cathelin
domain of the precursor protein (Figure 3). Most of the
mature cathelicidins are linear peptides that adopt an a-
helical fold with an amphipathic character when exposed
to hydrophobic environments (e.g., biological mem-
branes), but b-sheet structures stabilized by disulfide
bonds, loop structures or extended polyproline structures
are also known [104].
Cathelicidins were observed only in vertebrates to
date. Regarding mammals, their existence was demon-
strated in humans, monkeys, rabbits, rats, mice, guinea
pigs, pigs, cattle, sheep, goats, and horses [104]. Inten-
sively investigated cathelicidins are protegrins from
swine, indolicidin from cattle, human LL-37, CAP 18
from rabbits, and CRAMP from mice [103,105].
Cathelicidin genes span about 2 kb and contain four
exons. The fourth exon codes for the mature peptide
[103]. Each species contains a different set of cathelici-
din genes that are clustered in the genome, e.g., the
bovine genome contains eleven cathelicidin genes [24],
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cathelicidin gene in humans.
Cathelicidins are microbicidal against Gram-negative
and Gram-positive bacteria [107], fungi [108], enveloped
viruses [109], parasites [108], and tumor cells [110]. Unlike
most defensins, many cathelicidins display a bactericidal,
antiparasitic, and antiviral activity at physiological salt con-
centrations and are also active in the presence of serum
[103,104].
Permeabilization of bacterial membranes is a common
mode of action of cathelicidins. The antiviral activities
emerge through interactions of the peptides with viral
receptors or by disrupting the integrity of the viral envel-
ope. Additionally, they have chemotactic effects and are
able to recruit circulating leukocytes, neutrophils, and
monocytes. Cytotoxic effects have been reported for
some cathelicidins against eukaryotic cells (hematopoietic
cell lines, erythrocytes, and proliferating cells) [103,104].
3.5.1. Equine cathelicidins
Three cathelicidins of the horse have been investigated to
d a t e ,e C A T H - 1 ,e C A T H - 2 ,a n de C A T H - 3( t a b l e2 )
[35,111]. The cathelicidins were identified using RNA
from bone marrow [35]. The cDNA sequences of the
horse share 92-99% identity in the 5’-region and are
diverse at the mature peptide coding region (Figure 3).
The sequence of eCATH-3 is longer than those of
eCATH-1 and eCATH-2. Additionally, eCATH-3 com-
prises a short interspersed nucleotide element in the 3’-
UTR flanked by direct repeats and AT-rich microsatellites.
The presence of a retroposon and microsatellite sequences
in the eCATH-3 gene suggests that the genomic region is
unstable and may account for the generation of genetic
variations [35]. Investigations of the mRNA-expression
levels of the three cathelicidins in myeloid cells revealed
an abundant expression of eCATH-2 and e-CATH-3 and
a significantly lower level of eCATH-1.
Genetic analysis with more than 70 horses revealed that
50% of horses carry null alleles of eCATH-1 [35]. Polyclo-
nal antibodies against all three eCATH variants were gen-
erated using synthetic eCATH peptides. Western blotting
analysis revealed the existence of eCATH-2 and eCATH-3
peptides in all horses analyzed. On the contrary to expec-
tations, the eCATH-1 antibodies failed to recognize
eCATH-1 in both neutrophils and neutrophil granule
lysates. It was suggested that the eCATH-1 gene is unable
to encode a protein [35]. This finding was confirmed by
analyzing the ability of equine neutrophils to secrete
eCATH peptides. The analysis consistently revealed only
the presence of eCATH-2 and eCATH-3, further support-
ing that the eCATH-1 gene is non-functional.
Insights into the processing of the peptides were accu-
mulated by analyzing different samples of tracheobron-
chial secretions of horses affected by chronic obstructive
pulmonary disease (COPD) and acute bronchiolitis
[111]. Only eCATH-2 and eCATH-3 were detected,
being consistent with the observations of the first study.
Elastase was identified as the enzyme responsible for
processing cathelicidins of the horse.
The structure and activities of the three eCATH were
examined using synthetic peptides that corresponded to
the deduced sequences. Investigation of the secondary
structures by circular-dichroism spectroscopy confirmed
Figure 3 Amino-acid sequence alignment of selected mammalian cathelicidin precursors. Equine cathelicidins are shown in bold letters.
Conserved amino-acid residues are highlighted in grey. Mature peptides are underlined. The peptide structure of the mature peptides is given
at the end of each sequence. The signal peptide (light grey) and the cathelin domain (dark grey) are indicated by lines on top of the sequence
block. Species abbreviations: [ECA] = Equus caballus, [SSC] = Sus scrofa, [BTA] = Bos taurus, [HSA] = Homo sapiens, [OCU] = Oryctolagus cuniculus,
[MMU] = Mus musculus.
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peptides in the presence of a helicogenic solvent. In an
aqueous solution only eCATH-2 shows an a-helical con-
tent of 22.7%. When displayed as a helical wheel, all
three peptides displayed moderate amphipathicities [111].
The most bactericidal cathelicidin is the synthetic
eCATH-1 (that is not present in vivo) with minimal inhi-
bitory concentrations (MICs) between 3 and 12 μg/mL
for Gram-negative bacteria (including E. coli, Salmonella
enterica, Ps. aeruginosa, Kl. pneumoniae, and Ser. marces-
cens) and between 6 and 24 μg/mL for Gram-positive
bacteria (including Staph. aureus, Staph. epidermidis,
Strept. equines,a n dBac. megaterium). Equine CATH-2
was active against E. coli (14 μg/mL), Ser. marcescens
(28.5 μg/mL), Kl. pneumoniae (28.5 μg/mL), Staph. aur-
eus and Staph. epidermidis (57.0 and 28.5 μg/mL), and
Bac. megaterium (14 μg/mL). Surprisingly, eCATH-3
proved to be ineffective against all bacterial strains up to
peptide concentrations of 150 μg/mL. An antibacterial
activity was only observed when testing eCATH-3 in
low-ionic-strength medium [111].
Marked differences in antifungal activity were also
noticed. No equine cathelicidin showed activity against
Candida spp. or Pichia etchellsii. Cryptococcus spp. and
Rhodotorula rubra were sensitive to synthetic eCATH-1.
Equine CATH-2 only showed antifungal activities at phy-
siological salt concentrations, whereas CATH-3 was only
active in low salt medium. Based on previous reports that
point to a correlation between amphipathicity and antimi-
crobial activity [112], a slightly modified eCATH-3 peptide
was synthesized (LLK-eCATH-3) with a higher hydropho-
bic moment and helical content realized by the substitu-
tion of three amino-acid residues. These modifications
caused a dramatic change in the antimicrobial activity.
Antibacterial activities of LLK-eCATH-3 were comparable
with that of eCATH-1 (which was the most potent
eCATH) and antifungal effects were also noted at physio-
logical salt concentrations [111].
By reflecting the in vitro-data of these peptides some
questions inevitably arise. Curiously, the most potent pep-
tide in vitro (eCATH-1) is not present in equine myeloid
cells. However, an (increased) eCATH-1 expression might
occur only under particular conditions, e.g., after stimula-
tion by microbial antigens. Moreover, it cannot be
excluded that eCATH-1 might be expressed in other cell
types than myeloid cells as demonstrated for other mem-
bers of the cathelicidin family, e.g., the lung [113], squa-
mous epithelia [114], or in cancerous tissues [115].
Another point is the modest in vitro-activity of eCATH-3,
especially under physiological salt concentrations, even
though the peptide is present at high levels in vivo. Differ-
ent suggestions were made: first, the abundance of the
peptide at sites of release should be taken into account.
This is a common, but plausible statement to explain low
in vitro-activities or salt sensitivities, because most of the
antimicrobial peptides are produced for acting in short
time intervals and after release from storage granules the
peptides can locally reach remarkable high amounts as
known from defensins [116]. Additionally, eCATH-3 was
found in inflammatory secretions, indicating that the pep-
tide can also be released in extracellular fluids.
In addition to the cathelicidins 1 to 3, a fourth cathelici-
din sequence exists in the genome of the horse, recorded
and predicted by automated computational analysis
(NCBI’s Annotation Process: “similar to myeloid cathelici-
din 2”). The sequence seems to be incomplete. However,
the predicted amino acid sequence (denoted eCATH-4 in
this review) is included in Figure 3 and the corresponding
gene information in Table 2.
Recently, the existence of novel cathelicidin-derived
antimicrobial peptides from Equus asinus,t h eA f r i c a n
donkey, has been described (denoted EA-CATH1 and EA-
CATH2) [43]. The peptides were identified from a lung
cDNA library, suggesting that the eCATH-peptides could
possibly be found in tissues next to myeloid cells. The
mature peptides are composed of 25 and 26 residues com-
parable with eCATH-1 and eCATH-2. Chemically synthe-
sized EA-CATH1 exerts a potent antimicrobial activity in
the range of 0.3-2.4 μg/ml against various bacteria and
fungi, including clinically isolated drug-resistant strains.
EA-CATH1 is also active at physiological conditions and
does not show cytotoxic activity at concentrations up to
20 μg/mL (actually, this is a very low concentration for
testing hemolytic activities). EA-CATH1 possesses an a-
helical conformation in an acidic milieu.
The authors performed scanning-electron microscopy to
determine the mode of action of EA-CATH1 using Staph.
aureus as a model organism. The analysis revealed a rapid
disruption of the bacterial membrane. In addition, the
authors observed a possible restriction of bacterial coloni-
zation and spread caused by an exerted hem-agglutination
activity of EA-CATH1 in the presence of CaCl2,w h i c h
might potentiate an inhibition against bacterial interac-
tions with the host erythrocyte surface [43]. EA-CATH2
did not show antibacterial activity.
3.6. Defensins
The defensins represent the major class of antimicrobial
peptides in vertebrates. They are comprehensively
reviewed in [117-119]. Defensins are cationic and
cysteine-rich peptides with molecular masses ranging
from 3 to 5 kDa. The mature peptide consists of 18 to 45
amino acids and contains six highly conserved cysteine
residues forming characteristic intramolecular disulfide
bonds. The disulfide array is specific for the three defen-
sin sub-families in mammals: a-, b-, and θ-defensins
[117]. Alpha- and b-defensins consist of three antiparallel
b-sheets, whereas some b-defensins possess additionally
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between the defensin subgroups, there are crucial vari-
eties regarding their biology. An a-defensin synthesis is
presumably unique to a few tissues. They were found in
neutrophils [120], epithelial cells of the human female
urogenital tract [121], the kidney of rabbits [122], and in
the intestinal Paneth cells of different species [123].
Furthermore, their synthesis is limited to some species,
they were exclusively found in mammals (also basic ones
such as platypus) except cattle [124] and dogs [125]. In
contrast, b-defensins were observed in vertebrates,
arthropods, mollusks, and plants, where they are
expressed in various tissues [117]. The somewhat unusual
θ-defensins exhibit a cyclic b-sheet structure which is a
result of a posttranslational ligation of two truncated a-
defensin precursors [126]. Functional peptides were only
verified in non-human primates, whereas in all other
mammals the truncated a-defensin precursors have addi-
tional premature stop codons and are pseudogenes
[127,128].
Defensins are synthesized in vivo as inactive precursor
proteins. Proteolytic excision of the N-terminal inhibi-
tory anionic propeptide is required for maturation and
activation [19,20]. The mature defensins exhibit an anti-
microbial activity against a broad spectrum of microor-
ganisms including Gram-negative and Gram-positive
bacteria [117], fungi [13,129], and enveloped viruses
[130] in a concentration range of 0.1 to 5.0 μM. They
kill bacteria through an initial electrostatic interaction
with the negatively charged phospholipids of the micro-
bial cytoplasmatic membrane, followed by membrane
permeabilization, and finally lysis of the microbes [6,11].
The antimicrobial activity of most of the defensins was
reduced at increasing salt concentrations or in the pre-
sence of bivalent cations [131]. However, physiological
concentrations of 1 to 10 mg/mL peptide were measured
in leukocytes and in the lumen of crypts of Lieberkühn
and have been shown to kill microorganisms in vitro at
physiological salt concentrations [132]. Secretion of defen-
sins can be constitutive or induced by prokaryotic antigens
through a Toll-like-receptor mediated process [133]. In
addition, an induction after cytokine stimulation was
described which is often mediated by the transcription fac-
tors NF- B and STAT3 [26,27,134]. Moreover, defensins
are agonists for cytokine or chemokine receptors and
represent a link between the innate and adaptive immunity
[135-137].
The genetic anatomy of a-a n db-defensins exhibits a
conserved exon/intron-structure. They mostly consist of
two or three exons, respectively. The last exon codes for
the mature peptide. Defensin genes are arranged in clus-
ters. The number of individual genes varies widely
between species [41,138-140]. It is assumed that the spe-
cies-specific composition of defensin genes is a result of
evolutionary duplications and deletions from single genes
or genomic regions of the defensin cluster [141,142]. The
origin of the ancestral defensin gene is not finally clarified
[143,144].
3.6.1. Equine b-defensins
The first b-defensin of the horse was identified by Davis
et al. in 2004 [36]. It was denoted b-defensin-1 (later
renamed DEFB1). The derived amino-acid sequence
(peptide: eBD-1) shows the typical conserved cysteine
residues. Comparison with the cDNA sequences of
other b-defensins revealed 45-52% similarity to the
bovine, caprine, and porcine homologs, respectively. The
closest similarities were observed between eBD-1 and
human BD-2 or porcine BD-1.
DEFB1 expression was detected in different horse tissues
(Figure 1). Therefore, a constitutive expression was
assumed. The amplified products were not analyzed by
s e q u e n c i n g .T h u s ,i tc a n n o tb ee x c l u d e dt h a to t h e rb-
defensins or defensin-related products among DEFB1
were amplified. However, Davis et al. clearly demonstrated
expression of b-defensins in a variety of horse tissues [36].
The determined DEFB1 sequence was used to screen
the equine CHORI-241 BAC library [40]. The equine
BAC clone CH241-245H5 was selected for sequencing.
The clone comprised approximately 213 kb and was
mapped to ECA27q17. The sequence contained eight
potentially functional defensin genes (seven b-defensins
and one a-defensin gene), and five defensin-related pseu-
dogenes. The a-defensin was denoted DEFA5L (alpha-
defensin 5 like) because of the high similarity to the
human a-defensin DEFA5. Similarities of the b-defensins
were found with canine and rodent specific genes
(DEFL1 to DEFL3), as well as human b-defensins DEFB4,
encoding hBD3 (DEFB1 to DEFB3), and DEFB3,e n c o d -
ing hBD3 (DEFB103). The defensin-related pseudogenes
show premature stop codons, have start-codon mutations
or miss different conserved amino acids.
The authors demonstrated that equine b-defensins are
similarly organized as in other mammals and show the
typical genomic clustering [40]. A limitation of the study
was that all these sequences were not confirmed by tran-
scriptional analysis or by sequencing of the corresponding
equine cDNA.
A transcriptional analysis with equine DEFB1 was
already performed by Davis et al. [36]. DEFB2 as well as
DEFB3 are duplicates of DEFB1 [40]. The remaining b-
defensins (DEFL1, DEFL2, DEFL3, DEFB103)a n dt h ea-
defensin (DEFA5L) were analyzed by Bruhn et al. in 2008
using RNA from 14 different tissues of the horse [145].
The existing transcripts were verified for all defensins
except DEFL1 (Figure 1). Interestingly, DEFB103 was
exclusively transcribed in the tongue, indicating a special
oral defensin. The human DEFB103 is also expressed in
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antimicrobial activities.
Besides genomic studies and transcription analyses,
equine b-defensins were directly detected in glands and
glandular secretions. As lysozyme, b-defensins were
demonstrated to be products of the equine apocrine ceru-
minous- and sebaceous-glands and are suggested to be
involved in the function of cerumen as a general antimi-
crobial protective agent in the external auditory canal [72].
Two years later the detailed subcellular localization of
lysozyme and b-defensin in the apocrine glands of the
equine scrotal skin was analyzed [64]. Antimicrobial b-
defensins were localized in the secretory granules, the
Golgi apparatus and in the cisternae of the rough endo-
plasmatic reticulum. It was suggested that the presence
and secretion lead to a protective effect and a non-specific
defense against microorganisms exhibited by the apocrine
glands.
3.6.2. Equine a-defensins
The potentially functional a-defensin (DEFA5L)o nt h e
equine BAC clone CH241-245H5 [40] was duplicated
once producing the pseudogene DEFA5LP.T h et e r m
DEFA5L is based on the high identity (80.1%) to the
human Paneth cell-specific a-defensin DEFA5.F u r t h e r
striking similarities were observed with the rat neutrophil
peptide NP-2 (82.8%) and a-defensin 4 of the rhesus
monkey (79.1%). Conserved amino-acid residues (six
cysteines, one arginine, and one glutamate residue of
DEFA5L) show a sequential arrangement that is similar
to most other mammalian a-defensins [40].
The transcription of DEFA5L could be verified only in
the small intestine of the horse [42]. This specific tran-
scription of the peptide and the high similarity to the
human a-defensin DEFA5 leads to the assumption that it
is a Paneth-cell specific peptide. Sequencing of the amplifi-
cation products revealed two distinct cDNA sequences,
DEFA5L (already known from the BAC clone) and an
unknown sequence denoted as DEFA1. The putative pro-
peptides and mature peptides were predicted by compar-
ing the equine sequences to a-defensins of other species.
The mature DEFA1 peptide, presumed to be the more
active peptide, was recombinantly expressed in E. coli and
structurally characterized by CD spectroscopy and mole-
cular modeling [42]. It contains a small b-sheet, consisting
of three b-strands flanked by large unstructured regions
and stabilized by three intramolecular disulfide-bonds as
known with other a-defensins.
The antimicrobial activities were comprehensively
investigated (Table 3). It was shown that DEFA1 dis-
plays a broad spectrum of antimicrobial activity against
both fermenting and non-fermenting Gram-negative
strains, against Gram-positive cocci, spore-forming
bacilli, and the yeast Candida (C.) albicans. Remarkably,
DEFA1 was shown to be a potent peptide antibiotic
against Rhodococcus (Rh.) equi, Strep. equi,a n dSalmo-
nella choleraesuis [131]. Three different Rh. equi strains
were analyzed, including the highly infectious Rh. equi
85FP
+ strain. All strains were susceptible at low peptide
concentrations.
Salt sensitivity, as known from other defensins, was
also observed with equine DEFA1. Antimicrobial assays
p e r f o r m e da th i g h e rs a l tc o n c e n t r a t i o n su s i n gRh. equi
strains as target organisms resulted in a decreased anti-
microbial activity of DEFA1 [131].
DEFA1 rapidly permeates bacterial membranes at acidic
and neutral pH [42]. Pore-formation activity was demon-
strated. A membrane-selectivity of DEFA1 for negatively
charged membranes was examined using liposomes com-
posed of defined phospholipids. An intercalation and
insertion of the peptide into the liposome membrane was
only observed with phosphatidylglycerol and phosphatidyl-
serine (negative net charge), but not with sphingomyelin,
phosphatidylethanolamine, and phosphatidylcholine (neu-
tral net charge) [145]. Therefore, it was concluded that the
peptide might act preferentially on prokaryotic but not on
eukaryotic membranes.
3.6.3. Repertoire of equine a-defensins
Bruhn et al. analyzed the equine repertoire of a-defensins
in more detail [41]. They screened the equine genome in
silico for putative a-defensin genes using the known
DEFA5L and DEFA1 sequences as search matrices.
Twenty-nine different nucleotide sequences resembling a-
defensins were obtained from the “whole genome shot-
gun”-database of the horse.
Transcriptom analysis with cDNA from the small intes-
tine reveals 38 different equine intestinal a-defensin tran-
scripts. At least 20 of them code for functional peptides
due to the fact that typical conserved a-defensin charac-
teristics are present in the primary sequences. These
include the conserved cysteine residues, necessary for the
typical defensin disulfide-bond connectivity, an arginine
and a glutamate residue, forming a conserved salt bridge
[146,147], and a highly conserved glycine residue, which
is essential for correct folding [148]. At least one of these
a-defensin typical characteristics is missing in the mature
peptide segment within the remaining 18 sequences.
However, this does not inevitably lead to a loss of the
biological function of these a-defensins [147]. A
sequence alignment of the deduced mature peptides is
shown in Figure 4. Several of the equine a-defensins
(DEFA17, DEFA18/19, DEFA30L) resemble certain
cathelicidins observed in cattle, sheep, and goats [149],
because of proline-rich C-terminal extensions. Interest-
ingly, the premature stop codon of two transcripts
(DEFA35L, DEFA36L) is at the same position as that
observed for the a-defensin precursors involved in the
assembling of cyclic θ-defensins [126] and may indicate
an existence of θ-defensins outside primates [41].
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scripts revealed that ten transcripts lack genomic
sequences and 14 genomic sequences lack an appropri-
ate transcript. Moreover, for some transcripts single
exons are missing in the genomic database (EquCab
2.0). The authors explain these discrepancies with an
incomplete assembly of the horse genome. The tran-
scripts lacking genomic sequences could also be due to
copy number variations that have been reported for
human a-defensins [150], or an appropriate transcript
could be expressed in unexamined tissues and cells.
A comprehensive repertoire of intestinal a-defensins
l i k et h a ti nt h eh o r s ei sv e r yr a r e .T h eo n l yk n o w n
organism with a numerically related repertoire of
enteric a-defensins is the mouse. At least 23 different
peptides are known, named cryptdins and cryptdin-
related sequences [151,152]. They were not only found
in the small intestine but also in the large intestine, the
cecum, and the rectum. The biological relevance of
expressing such high amounts of different a-defensin
peptides in the gut remains unclear. Probably, the pep-
tides can exhibit different specificities against microor-
ganisms, as observed in mice [151], or the expression
level of the a-defensin genes along the intestinal tract
shows large variations to optimize the local regulation
of bacterial colonization [153]. This may result in an
extensive and optimized process of fermentation of the
nutriment.
The horse is to date the only known organism expres-
sing a-defensins within the group of Laurasiatheria.I t
remains an open question why for example cattle and
dogs presumably lost their complete set of a-defensin
genes while in the horse the number increased exten-
sively. Analysis regarding the presence or absence of a-
defensins in the closest relatives of the horse like tapir
and rhinoceros are missing. Obviously, the horse will
play an important role in studies analyzing the evolution
or functions of a-defensins.
Table 3 Antimicrobial activities of the equine a-defensin DEFA1
Test strain LD90 [μg/mL] MBC [μg/mL]
Gram-negative bacteria
E. coli ATCC 11775 0.8 1.6
E. coli ATCC 25922 0.8 1.6
E. coli ATCC 35218 0.2 1.6
E. coli D31 1.6 3.1
Kl. pneumoniae ATCC 13883 12.5 > 25*
Enterobacter cloacae ATCC 13047 25 > 25*
Ps. aeruginosa ATCC 10145 3.1 > 25*
Ps. aeruginosa NCTC 11440 6.2 12.5
Burkholderia cepacia ATCC 25416 > 25* > 25*
Salmonella choleraesuis subsp. typhimurium serovar Typhimurium 5 10
P. multocida subsp. multocida > 10* > 10*
Gram-positive bacteria
Staph. aureus ATCC 6538 1.6 3.1
Staph. aureus ATCC 12600 1.6 6.2
Staph. epidermidis ATCC 14990 3.1 6.2
Enterococcus faecalis ATCC 29212 0.8 25
Enterococcus faecalis PEG 205 (wild type) 1.6 12.5
Strept. pyogenes ATCC 12344 3.1 3.1
Strept. equi subsp. zooepidemicus 2.5 5
Strept. equi subsp. equi 2.5 5
Strept. dysgalactiae subsp. equisimilis 51 0
Rh. equi ATCC 33701 P
- 2.5 5
Rh. equi ATCC 33701 P
+ 2.5 5
Rh. equi 85 FP
+ 2.5 5
Bacillus megaterium ATCC 14581 0.2 0.8
Yeast
C. albicans ATCC 24433 3.2 3.2
The antimicrobial activities of DEFA1 were determined by micro dilution assays against different bacterial strains and C. albicans.L D 90 values (90% lethal dose)
and MBC values (minimal bactericidal concentration; ≥ 99.9% killing) are given. * = The maximal peptide concentration used in the assay was still below the LD90
or MBC, respectively.
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Hepcidins are cysteine-rich peptides involved in systemic
iron homeostasis by controlling iron absorption and
macrophage iron release. In addition they show antimicro-
bial activities against Gram-positive and Gram-negative
bacteria as well as fungi [154,155]. The first hepcidin was
identified as an antimicrobial agent in human blood filtrate
and denoted LEAP-1 (liver expressed antimicrobial pep-
tide) [154]. As the name implies, hepcidins are predomi-
nantly expressed in the liver, but they are also found in
much smaller amounts in the heart, brain, lung [154], and
body fluids like urine [156]. An upregulation of hepcidins
during acute inflammation and in response to experimen-
tal inflammatory stimuli as well as IL-6 was observed
[155].
Hepcidins are synthesized as precursor peptides; the
active form is the mature peptide consisting of 20-30
amino acids. Mature hepcidins share eight conserved
cysteine residues across mammalian species, forming four
intramolecular disulfide bonds [156]. Basic amino acids
confer a positive net charge [155]. The human mature
peptide consists of two antiparallel b-sheets linked by a
hairpin loop resulting in an amphipathic peptide [157].
In mammals hepcidins share no significant sequence
homologies to any of the known antimicrobial peptides,
but they resemble structurally some insect defensins and
defensin-like drosomycin (from Drosophila melanoga-
ster) [155,156]. It was suggested that hepcidin may be a
vertebrate counterpart of cysteine-rich antimicrobial
peptides produced in the fat body of insects due to the
fact that the fat body of insects is the equivalent of the
mammalian liver [156].
3.7.1. Equine hepcidin
The equine hepcidin was identified using liver cDNA
samples of healthy horses and primer sequences derived
from known hepcidin sequences [158]. The equine DNA
sequence shows an identity of 74% to Bos taurus hepcidin
and 70% to hepcidin from Sus scrofa and Canis lupus
familiaris. It was determined that equine hepcidin is
located on Equus caballus chromosome ten and consists
of three exons. Real-time PCR analysis showed a high
expression in the liver and a much lower expression
(approximately -10
5) in the cervical spinal cord, cerebral
cortex, lung, duodenum, stomach, spleen, kidney, skeletal
muscle, and bladder [158].
The equine precursor peptide consists of 86 amino acids,
the predicted mature peptide of 25 amino acids. The
sequence shows eight conserved cysteine residues, as
known from other hepcidins and is 76% identical to bovine,
porcine, and human hepcidin [158]. The antimicrobial
Figure 4 Comparison of mature a-defensin amino-acid sequences of the horse. Sequences of a-defensin precursors that share 100%
identity within the mature peptide were combined, e.g., DEFA1 and DEFA2 = DEFA1/2. Gaps introduced to maximize amino-acid alignments are
indicated by hyphens. Conserved residues are highlighted: cysteine residues are colored red; arginine and glutamic acid, forming an
intramolecular salt bridge, are colored light grey; glycine is marked in dark grey. Defensin-like peptides are shown in italics. Premature stop
codons are indicated by asterisks. Numbers at the end of each sequence indicate the total number of amino acids followed by the net charge
at pH 7.5. DEFA37L is not shown because of a premature stop codon in the propeptide.
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hitherto not determined.
4. Antimicrobial peptides of vertebrates in
practice and clinical studies
In contrast to the great number of studies describing
impressive in vitro-activities of antimicrobial peptides,
only few reports exist about in vivo-experiments or
practical applications. One reason could be that in vivo-
studies are much more expensive and sophisticated.
Additionally, antimicrobial peptides in general have
some remarkable disadvantages that are described here
briefly together with some selected successful clinical
trials made with antimicrobial peptides of vertebrates.
Peptides of the horse have not yet been included in pre-
clinical or clinical studies.
4.1. Advantages of antimicrobial peptides as therapeutic
drugs in general
i, The mode of action finally aims at a fundamental struc-
ture of the target cell, the bacterial membrane. The mem-
brane is much more difficult to rearrange than intracellular
metabolic pathways. Therefore, the development of resis-
tances is rare.
ii, Some antimicrobial peptides simultaneously exhibit
antibacterial, antifungal, and antiviral activities. In the
case of multiple infections, only one therapeutic agent
might be needed. Additionally, antibacterial peptides can
act against a broad spectrum of Gram-positive and
Gram-negative bacteria in parallel.
iii, Many antimicrobial peptides are induced by stimu-
lants. A prophylactic vaccination is possible.
4.2. Disadvantages of antimicrobial peptides as
therapeutic drugs in general
i, Antimicrobial peptides generally are susceptible to
proteolytic degradation. Therefore, a systemic applica-
tion might be difficult to manage.
ii, Peptides are cytotoxic against host cells in some
cases. Studies regarding cytotoxicity are rare compared to
the numerous reports describing antimicrobial activities.
iii, Antimicrobial activities are often influenced by salt
concentrations, pH-value, and/or plasma proteins. Some
peptides with prominent antimicrobial potencies under
low-salt conditions lose their activities at physiological salt
conditions and/or in serum (due to interactions with
serum proteins).
4.3. Antimicrobial peptides of vertebrates in human
clinical trials
Despite the disadvantages, some antimicrobial peptides
have reached clinical trials. Among them is a derivative
(MSI-78) of magainin, isolated from the skin of the African
clawed frog Xenopus laevis,d e n o t e dP e x i g a n a n ,f o rt h e
treatment of impetigo contagiosa and diabetic foot ulcer
[159-162]. A derivate (IB-367) of pig protegrin, denoted
Iseganan, is used for the treatment of oral mucositis [163].
Neuprex (a derivate of the human bactericidal permeability
protein, rBPI23) is used for the treatment of sepsis, and
Omiganan against catheter associated infections (adminis-
tered as a 2% gel) [164,165]. Omiganan is a variant of indo-
licidin from cattle (CPI-226). Actually, only Pexiganan and
Omiganan show a significant effectivity compared to con-
ventional antibiotics in the third phase of clinical trials.
Consequently, it seems that the most lucrative applica-
tion of antimicrobial peptides and proteins is a local
treatment rather than a systemic application. Normally,
the peptides act in short time intervals and concomitant
high concentrations before they become degraded or
bound to other peptides.
Recent patents including antimicrobial peptides and
possible applications are reviewed in [166].
5. Equine candidates for development of
therapeutic applications: capabilities and
prospects
Equine antimicrobial peptides have not yet been subjected
to clinical experiments. Accordingly, data of equine anti-
microbial peptides represent basic research. The current
knowledge on antimicrobial peptides of the horse is too
limited to discuss them as a source for peptide antibiotics
in general. Nevertheless, they represent a promising tool
to treat infectious diseases of the horses themselves, espe-
cially if multiresistant strains are involved. A homologous
use of peptide antibiotics minimizes the risk of immunolo-
gic incompatibility that might occur in the case of hetero-
logous use. The administration of antimicrobial peptides
across species barriers is theoretically possible, but this
requires a comprehensive modification of the molecules.
Anyway, successful clinical studies in humans performed
with several antimicrobial peptides of vertebrates clearly
demonstrate that they are suitable for therapeutical
applications.
Potentials for practical applications of equine antimicro-
bial peptides in horses can be deduced from results
obtained with antimicrobial peptides in general. Advanta-
geously, the equine innate immune system and its antimi-
crobial peptides show some remarkable features offering
particular chances, for example the high number of a-
defensins in the intestine. The probably most promising
equine peptides that might influence veterinary medicine
are lysozymes, NK-lysin, cathelicidins, and defensins.
5.1. Equine lysozyme
Equine lysozyme expression was detected in many dif-
ferent organs of the horse (Figure 1). Its association
with horse disease patterns has been proven, albeit by
only recording its expression levels. Moreover, the
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cells and neutrophils emphasize its implication into the
innate immune defense of the horse. However, there is
yet no clear suggestion for the therapeutical use of this
enzyme in the horse or beyond. Closest to a putative
clinical application would be the use of the lysozyme
activity as an indicator of inflammation in cases of acute
joint injury as suggested by Torbeck and Prieur [59]. Of
course this would not address the antimicrobial activity
of the EL directly and it is restricted to horses. Another
approach that would also not address the classical anti-
microbial function is the use of cytotoxic activity. A
detailed investigation of the functions and properties of
cytotoxic ELOA might be used profitably in various bio-
technological applications with the potential to specifi-
cally target undesirable cells [70].
Nevertheless, the equine lysozyme is probably one of the
most promising candidates for a putative therapeutical use
with respect to the knowledge gathered in other species.
On the one hand, lysozymes directly mediate resistance to
bacterial infections as demonstrated in mice and humans
[167-170]. On the other hand, lysozymes possess immuno-
modulatory, anti-inflammatory functions [171] and they
can modulate the microflora of the gut [172,173]. The lat-
ter can be easily achieved by oral administration and was
found to decrease stress symptoms in hens after vaccina-
tion (patent: DE2907236C2). These data clearly represent
the potential that equine lysozyme might have.
5.2. Equine NK-lysin
As shown by Davis et al. [82], equine NK-lysin is upregu-
lated after intravenous administration of non-viable Pb.
acnes (see also section 3.2.). Pb. acnes has been used as
an immunostimulant in horses for almost two decades,
and beneficial responses to Pb. acnes administration have
been characterized by clinical treatment of non-specific
respiratory disease [84,174]. The use of Pb. acnes com-
bined with an antimicrobial therapy leads to an overall
success rate of over 90%, in contrast to a recovery rate of
less than 50% if horses are treated with antibiotics alone.
The successful clinical trials illustrate that the stimulation
of the immune system has a significant influence on the
recovery and health of horses. Davis et al. [82] showed
that antimicrobial peptides, especially NK-lysin, are
included in this process. The development of more speci-
fic stimulators influencing the synthesis of antimicrobial
peptides could be an attractive possibility for the treat-
ment and prevention of infectious diseases.
The antimicrobial potencies of the equine NK-lysin are
hitherto not determined. But with respect to the common
high activity against microbes and cancer cells determined
in other species one may assume that equine NK-lysin
employs an equivalent activity and mode of action.
Of particular interest is that NK-lysin fragments and
derivates also show potent antimicrobial activities by con-
current optimization of peptide stability and minimized
cytotoxicity. NK-2, a fragment of the porcine NK-lysin,
comprising the a-helical, cationic core region, is a very
efficient antimicrobial agent and, on the contrary to nat-
ural NK-lysin, has only little hemolytic and cytotoxic activ-
ities. NK-2 is also able to preferentially kill cancer cells and
exhibits antimicrobial activity against intracellular patho-
gens. It was designated as a promising candidate for clini-
cal applications [175,176] and novel antiinfectives [177].
The importance of equine NK-lysin in the immune reg-
ulation of the horse was demonstrated already. The suc-
cessful investigations of NK-lysins of other species should
encourage the equine veterinary researchers to study the
equine NK-lysin in more detail.
5.3. Equine cathelicidins
The equine cathelicidins are, next to the equine defen-
sins, the most potent antimicrobials with a broad spec-
trum activity against bacteria. Compared to the defensins
they have additional advantages. The cathelicidins
eCATH-1 and eCATH-2 are not salt sensitive [35]. The
salt and plasma tolerance of these peptides in combina-
tion with their high antimicrobial activities make them
interesting candidates for further preclinical studies.
Especially, the properties of the most bactericidal peptide
eCATH-1 are promising. Curiously, eCATH-1 was not
present at the peptide level in the horse population ana-
lyzed by Scocci et al. [35]. To our knowledge, it is not
known whether an active eCATH-1 is present in some
breeds. However, the expression of an additional catheli-
cidin antimicrobial peptide, or the overexpression of a
cathelicidin gene protects transgenic mice against bacter-
ial skin infections [178]. It may be interesting to study
the inducibility of eCATH-1 in horses which carry func-
tional alleles and whether null alleles are associated with
a higher susceptibility for infections. Recent investiga-
tions showed that cathelicidins are inducible by vitamin
D3. Moreover, the vitamin-D3 pathway was identified as
one of the major regulators of cathelicidins [179,180].
This may provide new basic approaches for the therapy
of equine infectious diseases.
The possibility for the optimization of equine catheli-
cidins was impressively demonstrated by Skerlavaj et al.
[111]. A slight modification of the eCATH-3 peptide
(LLK-eCATH-3) realized by the substitution of only
three amino acids caused a higher hydrophobicity and
helical content resulting in a dramatic change of the
antimicrobial activity. Antibacterial activities of LLK-
eCATH-3 were comparable to those of eCATH-1
(eCATH-3 without modifications lacks antibacterial
activities) and antifungal effects were noted.
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Data about the antimicrobial properties of equine b-
defensins are missing. However, one peptide should be
mentioned here: the oral b-defensin DEFB103.T r a n -
scriptional analysis shows that DEFB103 is exclusively
expressed in the tongue of the horse [145]. It seems to
be a specialized peptide that possibly has an optimized
spectrum of activity against oral pathogens and prevents
the invasion of pathogens into the digestive tract. The
human homolog (DEFB103, encoding hBD-3) is also
synthesized in oral epithelia and was analyzed compre-
hensively. It shows strong antimicrobial properties
within the group of defensins against a broad spectrum
of microbes, including bacteria and fungi [181]. It is
stable against proteolytic digestion and its activity is
almost not affected by physiological salt concentration
[182]. Therefore equine DEFB103 might be a promising
candidate for initial analysis of equine b-defensins.
5.5. Equine a-defensins
T h eo n l yi n t e n s i v e l ys t u d i e de q u i n ea-defensin is
DEFA1. The antimicrobial properties are comparable to
conventional antibiotics [131] and the spectrum of activ-
ity includes numerous bacteria and C. albicans [42]. The
stability against digestion and cytotoxicity remains
unclear, but it was shown that DEFA1 only interacts
with negatively charged liposomal membranes serving as
model for bacterial membranes. Interestingly, the pep-
tide has a potent antimicrobial activity against typical
horse pathogens, most notably Rh. equi. DEFA1 kills
three different Rh. equi strains, including the highly
infectious Rh. equi 85 FP
+,a n dt h eb-lactam antibiotic
resistant strains Rh. equi ATCC 33701 P
+ at comparable
peptide concentrations. The efficacy of DEFA1 is higher
than that of the antimicrobial peptide magainin II and
the conventional antibiotics ampicillin, clarithromycin or
rifampicin, typically used for treatment of Rh. equi
pneumonia [131].
Rh. equi mostly infects the lung of the horse, while a
potential molecular weapon against the pathogen is
located in the intestine. It might be possible to treat the
infected lung of foals with DEFA1 applied as an aerosol.
Aerosolization methods have not yet been used in horses
for administration of antimicrobial peptides, but they were
applied for conventional antibiotics [183]. In tuberculosis,
a close model for rhodococcosis, nebulization of capreo-
mycin was effective to treat the disease in a guinea pig
model [184]. Although nothing is known about the effi-
cacy and required concentration of DEFA1 treatment in
the lower airways of horses, nebulization might be a possi-
ble application. First investigations are currently being per-
formed using a mouse model with artificial induced lung
infections. The focus is on the in vivo-treatment of Rh.
equi infections, but human pathogens are also being used.
If these investigations are successful, further in vivo analy-
sis with horses are conceivable.
Furthermore, DEFA1 is only one candidate out of
numerous other potentially functional a-defensins in the
intestine of the horse, but nothing is known about their
antimicrobial properties [41]. As shown in Figure 4
some of the mature peptides exhibit a high positive
charge, which possibly strengthens the interaction
between the peptide and the bacterial cell membrane.
Some other promising candidates of equine a-defensins
are currently synthesized recombinantly to analyze and
compare their potencies.
Paneth cell a-defensins like DEFA1 play an important
role in infectious diseases of the gut. Studies in humans
show an enhanced expression of a-defensin genes in
colonic inflammations [185]. Wehkamp et al. discovered
a reduced Paneth cell a-defensin synthesis in ileal
Crohn disease, a chronic disease of the intestine [186],
and Ferguson et al. found that single nucleotide poly-
morphisms confer susceptibility to inflammatory bowel
disease [187].
Inflammatory bowel diseases have also been described
in horses, for example the duodenitis/proximal jejunitis
syndrome characterized by catarrhal enteritis with muco-
sal hyperemia or necrosis. Another example is colitis
causing intramural edema and hemorrhagic inflamma-
tion of the large intestine. Bacteria have been implicated
as etiological agents of both diseases. It will be interesting
to analyze the relation between enteric infectious diseases
of the horse and a possible deficiency or dysregulation of
Paneth cell a-defensins. The high quantity of equine
intestinal a-defensins and the biological activity of
enteric DEFA1 against microorganisms emphasizes the
importance of equine intestinal defensins in the protec-
tion of the horse against infections of the intestinal tract
and the regulation of the intestinal microbiome,
respectively.
Whether copy number variations, nucleotide poly-
morphisms, or functional mutations of equine a-defensins
influence health or performance of horses is unknown.
Further investigations are not only of interest for veterin-
ary science and practice, but rather also for animal bree-
ders who are interested in a marker-based selection to
preserve and enhance equine health.
Conclusions
With the objective of discovering new antimicrobial agents
in fighting the threatening rise of multidrug-resistant
pathogens, so-called super-bugs, antimicrobial peptides
and proteins appear most promising. Despite millions of
years of evolution, microorganisms failed to develop com-
mon resistance strategies protecting them against these
molecules. The number of investigations on the identifica-
tion and isolation of equine antimicrobial peptides during
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Page 17 of 22the last decades is pretty small. But recent studies clearly
show that the horse represents a rich source of antimicro-
bial peptides and proteins, especially defensins, of potential
therapeutic use.
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